Key Points
- Humacyte insider sale: Insider Shamik Parikh sold 45,887 shares of HUMA at an average price of $0.90, totaling about $41,298. The sale reduced his ownership by 14.4% and was done to cover tax withholding tied to vesting equity awards.
- Recent earnings beat estimates, but revenue missed: Humacyte reported a quarterly loss of $0.09 per share, slightly better than expected, while revenue came in at $0.50 million versus the $1.46 million consensus estimate. The company also continues to post substantial negative margins and return on equity.
- Analyst sentiment remains mixed but mostly positive: Seven analysts rate the stock a Buy and one rates it Sell, with a MarketBeat average rating of Moderate Buy and an average price target of $7.57. However, some firms have recently cut targets or lowered ratings.
Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) insider Shamik Parikh sold 45,887 shares of the firm's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the transaction, the insider directly owned 272,713 shares in the company, valued at $245,441.70. This trade represents a 14.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Humacyte Stock Performance
Shares of HUMA opened at $0.92 on Thursday. The firm has a 50-day moving average price of $0.84 and a 200 day moving average price of $1.04. The firm has a market capitalization of $203.64 million, a PE ratio of -1.61 and a beta of 2.31. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. Humacyte, Inc. has a 52-week low of $0.55 and a 52-week high of $2.93.
Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. On average, sell-side analysts anticipate that Humacyte, Inc. will post -0.32 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
HUMA has been the subject of a number of research reports. Wall Street Zen raised Humacyte from a "strong sell" rating to a "sell" rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Humacyte in a research note on Friday, April 10th. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research report on Tuesday, April 28th. Benchmark reduced their price objective on shares of Humacyte from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, January 21st. Finally, BTIG Research lowered their price objective on shares of Humacyte from $3.00 to $2.00 and set a "buy" rating on the stock in a research note on Wednesday, May 13th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Humacyte has an average rating of "Moderate Buy" and an average target price of $7.57.
View Our Latest Report on HUMA
Institutional Investors Weigh In On Humacyte
Several large investors have recently modified their holdings of HUMA. R Squared Ltd acquired a new position in shares of Humacyte in the 4th quarter worth $25,000. Atom Investors LP purchased a new stake in shares of Humacyte during the fourth quarter valued at $25,000. Truist Financial Corp purchased a new stake in shares of Humacyte during the third quarter valued at $28,000. Prudential Financial Inc. acquired a new position in shares of Humacyte in the 2nd quarter valued at $28,000. Finally, Financial Advisors Network Inc. purchased a new position in Humacyte in the 2nd quarter worth about $28,000. 44.71% of the stock is owned by institutional investors.
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.
The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
